RESUMEN
We report the measurement of the helicity asymmetry E for the pπ^{0} and nπ^{+} final states using, for the first time, an elliptically polarized photon beam in combination with a longitudinally polarized target at the Crystal Ball experiment at MAMI. The results agree very well with data that were taken with a circularly polarized photon beam, showing that it is possible to simultaneously measure polarization observables that require linearly (e.g., G) and circularly polarized photons (e.g., E) and a longitudinally polarized target. The new data cover a photon energy range 270-1400 MeV for the pπ^{0} final state (230-842 MeV for the nπ^{+} final state) and the full range of pion polar angles, θ, providing the most precise measurement of the observable E. A moment analysis gives a clear observation of the pη cusp in the pπ^{0} final state.
RESUMEN
A precise measurement of the differential cross sections dσ/dΩ and the linearly polarized photon beam asymmetry Σ_{3} for Compton scattering on the proton below pion threshold has been performed with a tagged photon beam and almost 4π detector at the Mainz Microtron. The incident photons were produced by the recently upgraded Glasgow-Mainz photon tagging facility and impinged on a cryogenic liquid hydrogen target, with the scattered photons detected in the Crystal Ball/TAPS setup. Using the highest statistics Compton scattering data ever measured on the proton along with two effective field theories (both covariant baryon and heavy-baryon) and one fixed-t dispersion relation model, constraining the fits with the Baldin sum rule, we have obtained the proton electric and magnetic polarizabilities with unprecedented precision: α_{E1}=10.99±0.16±0.47±0.17±0.34, ß_{M1}=3.14±0.21±0.24±0.20±0.35; in units of 10^{-4} fm^{3} where the errors are statistical, systematic, spin polarizability dependent, and model dependent.
RESUMEN
Meconium peritonitis is a rare prenatal disease with an increased rate of morbidity and mortality in the neonatal period. Distinctive features revealed by prenatal and postnatal ultrasoundmay be present: abdominal calcifications, ascites, polyhydramnios, meconium pseudocyst, echogenic mass and dilated bowel or intestinal obstruction. Establishing clear postnatal treatment and prognosis is difficult because of the heterogeneity of the results obtained by ultrasound. The aim of the study is to determine how prenatal diagnosis of meconium peritonitis is associated with perinatal management and further evolution. Clinical results are different depending on the presence of antenatal diagnosis of meconium peritonitis and its form, which can be mild or severe. Surgical treatment and management of meconium peritonitis depend on the clinical presentation of the newborn. Meconium peritonitis diagnosed prenatally differs from that of the newborn, not only concerning the mortality rates but also through reduced morbidity and overall better prognosis.
Asunto(s)
Enfermedades Fetales/diagnóstico por imagen , Enfermedades del Recién Nacido/diagnóstico por imagen , Meconio , Peritonitis/diagnóstico por imagen , Peritonitis/cirugía , Atención Posnatal , Ultrasonografía Prenatal , Femenino , Edad Gestacional , Humanos , Recién Nacido , Obstrucción Intestinal/diagnóstico por imagen , Obstrucción Intestinal/cirugía , Masculino , Peritonitis/diagnóstico , Peritonitis/etiología , Embarazo , Pronóstico , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
A newborn with abdominal wall defect is one of the most dramatic cases in neonatology, but also a challenge for pediatric surgeons. This article describes the fundamental concepts of two major abdominal wall defects - gastroschisis and omphalocele - including options and principles of prenatal and postnatal care. Although these birth defects of the abdominal wall are always grouped together, they are two separate and distinct entities, with many differences in terms of pathology and associated anomalies; this explains the different therapeutic approach and results. For a correct management of the newborn with this anomaly, it is essential to understand the similarities and differences between gastroschisis and omphalocele. This article emphasises the similarities between these two parietal defects, highlighting the differences as well.
Asunto(s)
Pared Abdominal/anomalías , Gastrosquisis/diagnóstico , Hernia Umbilical/diagnóstico , Pared Abdominal/cirugía , Acetilcolinesterasa/metabolismo , Biomarcadores/sangre , Diagnóstico Diferencial , Gastrosquisis/sangre , Gastrosquisis/cirugía , Hernia Umbilical/sangre , Hernia Umbilical/cirugía , Humanos , Recién Nacido , Pronóstico , Resultado del Tratamiento , Ultrasonografía Prenatal , alfa-Fetoproteínas/metabolismoRESUMEN
BACKGROUND AND PURPOSES: Erythropoietin (EPO) has been shown to protect against myocardial infarction in animal studies by activating phosphatidylinositol-3 kinase (PI3K)/Akt and ERK1/2. However these pro-survival pathways are impaired in the diabetic heart. We investigated the ability of EPO to protect human atrial trabeculae from non-diabetic and diabetic patients undergoing coronary artery bypass surgery, against hypoxia-reoxygenation injury. EXPERIMENTAL APPROACH: Human atrial trabeculae were exposed to 90min hypoxia and 120min reoxygenation. EPO was administered throughout reoxygenation. The developed force of contraction, calculated as a percentage of baseline force of contraction, was continuously monitored. The involvement of PI3K and ERK1/2 and the levels of activated caspase 3(AC3) were assessed. KEY RESULTS: EPO improved the force of contraction in tissue from non-diabetic patients (46.7+/-1.7% vs. 30.2+/-2.2% in control, p<0.001). These beneficial effects were prevented by the PI3K inhibitor, LY294002 and the ERK1/2 inhibitor, U0126. EPO also significantly improved the force of contraction in the diabetic tissue, although to a lesser degree. The levels of activated caspase 3 were significantly reduced in EPO treated trabeculae from both non-diabetic and diabetic patients, relative to their respective untreated controls. CONCLUSIONS AND IMPLICATIONS: EPO administered at reoxygenation protected human myocardial muscle by activating PI3K and ERK1/2 and reducing the level of activated caspase 3. This cardioprotection was also observed in the diabetic group. This data supports the potential of EPO being used as a novel cardioprotective strategy either alone or as an adjunct in the clinical setting alongside existing reperfusion therapies.
Asunto(s)
Eritropoyetina/farmacología , Corazón/efectos de los fármacos , Proteína Quinasa 1 Activada por Mitógenos/fisiología , Proteína Quinasa 3 Activada por Mitógenos/fisiología , Daño por Reperfusión Miocárdica/prevención & control , Fosfatidilinositol 3-Quinasas/fisiología , Adulto , Anciano , Caspasa 3/fisiología , Activación Enzimática , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proteínas Proto-Oncogénicas c-akt/fisiología , Proteínas RecombinantesRESUMEN
BACKGROUND: Necrostatin (Nec-1) protects against ischemia-reperfusion (IR) injury in both brain and heart. We have previously reported in this journal that necrostatin can delay opening of the mitochondrial permeability transition pore (MPTP) in isolated cardiomyocytes. AIM: The aim of the present study was to investigate in more detail the role played by the MPTP in necrostatin-mediated cardioprotection employing mice lacking a key component of the MPTP, namely cyclophilin-D. METHOD: Anaesthetized wild type (WT) and cyclophilin-D knockout (Cyp-D-/-) mice underwent an open-chest procedure involving 30 min of myocardial ischemia and 2 h of reperfusion, with subsequent infarct size assessed by triphenyltetrazolium staining. Nec-1, given at reperfusion, significantly limited infarct size in WT mice (17.7 +/- 3% vs. 54.3 +/- 3%, P < 0.05) but not in Cyp-D-/- mice (28.3 +/- 7% vs. 30.8 +/- 6%, P > 0.05). CONCLUSION: The data obtained in Cyp-D-/- mice provide further evidence that Nec-1 protects against myocardial IR injury by modulating MPTP opening at reperfusion.
Asunto(s)
Ciclofilinas/fisiología , Imidazoles/farmacología , Indoles/farmacología , Proteínas de Transporte de Membrana Mitocondrial/fisiología , Daño por Reperfusión Miocárdica/prevención & control , Animales , Masculino , Ratones , Poro de Transición de la Permeabilidad MitocondrialRESUMEN
Myocardial ischaemia/reperfusion injury leading to myocardial infarction is one of the most frequent causes of debilitation and death in man. Considerable research has been undertaken to investigate the possibility of reducing myocardial infarction and increasing cell survival by activating certain endogenous prosurvival signaling pathways. Thus, it has been established that the activation of the PI3K (Phosphoinositide-3 kinase)/Akt (Protein kinase B, PKB) signaling pathway is essential for protection against ischaemia/reperfusion injury. This pathway has been shown to be activated by mechanical procedures (e.g. pre and post conditioning) as well as by a number of pharmacological agents. Although the activation of this prosurvival signaling pathway induces the phosphorylation of a large number of substrates implicated in increased cell survival, when activated over a prolonged period this pathway can have detrimental consequences by facilitating unwanted growth and malignancies. Importantly PTEN (phosphatase and tensin homolog deleted on chromosome ten), is the main phosphatase which negatively regulates the PI3K/Akt pathway. In this review we discuss: a) the significance and the limitations of inhibiting PTEN in myocardial ischaemia/reperfusion injury; b) PTEN and its relationship to ischaemic preconditioning, c) the role of PTEN in the development of tolerance to chronic administration of drugs known to limit infarction by activating PI3K/Akt pathway when given acutely, and d) the possible role of PTEN in the ischaemic/reperfused diabetic heart. The experimental evidence discussed in this review illustrates the importance of PTEN inhibition in the protection of the heart against ischaemia/reperfusion injury.
Asunto(s)
Daño por Reperfusión Miocárdica/metabolismo , Fosfohidrolasa PTEN/metabolismo , Animales , Humanos , Hipertrofia , Precondicionamiento Isquémico Miocárdico , Miocardio/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismoRESUMEN
BACKGROUND AND PURPOSE: Protection against ischaemia-reperfusion (I/R) injury involves PI3K-Akt and p44/42 MAPK activation. Leptin which regulates appetite and energy balance also promotes myocyte proliferation via PI3K-Akt and p44/42 MAPK activation. We, therefore, hypothesized that leptin may also exhibit cardioprotective activity. EXPERIMENTAL APPROACH: The influence of leptin on I/R injury was examined in perfused hearts from C57Bl/6 J mice that underwent 35 min global ischaemia and 35 min reperfusion, infarct size being assessed by triphenyltetrazolium chloride staining. The concomitant activation of cell-signalling pathways was investigated by Western blotting. The effect of leptin on mitochondrial permeability transition pore (MPTP) opening was studied in rat cardiomyocytes. KEY RESULTS: Leptin (10 nM) administered during reperfusion reduced infarct size significantly. Protection was blocked by either LY294002 or UO126, inhibitors of Akt and p44/42 MAPK, respectively. Western blotting confirmed that leptin stimulated p44/42 MAPK phosphorylation significantly. Akt phosphorylation was also enhanced but did not achieve statistical significance. Additionally, leptin treatment was associated with a significant increase in p38 phosphorylation. By contrast, leptin caused downregulation of phosphorylated and non-phosphorylated STAT3, and of total AMP-activated kinase. Cardiomyocytes responded to leptin with delayed opening of the MPTP and delayed time until contracture. CONCLUSIONS AND IMPLICATIONS: Our data indicate for the first time that the adipocytokine, leptin, has direct cardioprotective properties which may involve the PI3-Akt and p44/42 MAPK pathways.
Asunto(s)
Cardiotónicos , Leptina/farmacología , Daño por Reperfusión Miocárdica/prevención & control , Animales , Western Blotting , Técnicas In Vitro , Masculino , Ratones , Ratones Endogámicos C57BL , Mitocondrias Cardíacas/efectos de los fármacos , Mitocondrias Cardíacas/metabolismo , Daño por Reperfusión Miocárdica/patología , Miocardio/patología , Miocitos Cardíacos/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Fosforilación , Ratas , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacosRESUMEN
Apoptosis contributes to myocardial cell death during ischemia and reperfusion, especially during reperfusion. Growth factor "survival" signaling attenuates apoptosis. We therefore examined the effects of transforming growth factor-beta1 (TGF-beta1) on reperfusion injury and assessed the role of p42/p44 MAPK signaling in TGF-beta1-induced protection. Rat ventricular myocytes were subjected to hypoxia and reoxygenation. TGF-beta1 (0.2 ng/ml) was applied to cells during reoxygenation and the extent of apoptosis was determined by TUNEL and annexin V binding assays. Further studies were conducted in intact rat hearts subjected to regional ischemia and reperfusion. TGF-beta1 (0.2 ng/ml) was perfused during early reperfusion. In cells, incubation with TGF-beta1 (0.2 ng/ml) during reoxygenation attenuated the extent of cell membrane damage (trypan blue uptake) and also reduced the numbers of TUNEL-and annexin V-positive cells. Reduction of apoptosis was abrogated by PD98059 (5 microM), an inhibitor of p42/p44 MAPK activation. TGF-beta1 activated p42/p44 MAPK transiently in normoxic myocytes. When intact hearts received TGF-beta1 (0.2 ng/ml) during early reperfusion, infarct size was reduced from 39.4 +/- 3.1% to 17.3 +/- 3.1% (p < 0.01). This protective action of TGF-beta1 was abrogated by PD98059. These studies are the first to show that TGF-beta attenuates cardiac myocyte apoptosis during early reperfusion and limits infarct size through p42/p44 MAPK activation.
Asunto(s)
Proteína Quinasa 1 Activada por Mitógenos/fisiología , Proteínas Quinasas Activadas por Mitógenos/fisiología , Daño por Reperfusión Miocárdica/prevención & control , Miocardio/enzimología , Factor de Crecimiento Transformador beta/uso terapéutico , Animales , Animales Recién Nacidos , Apoptosis/efectos de los fármacos , Hipoxia de la Célula , Células Cultivadas , Inhibidores Enzimáticos/farmacología , Flavonoides/farmacología , Etiquetado Corte-Fin in Situ , Masculino , Proteína Quinasa 1 Activada por Mitógenos/antagonistas & inhibidores , Proteína Quinasa 3 Activada por Mitógenos , Proteínas Quinasas Activadas por Mitógenos/antagonistas & inhibidores , Infarto del Miocardio/patología , Infarto del Miocardio/prevención & control , Daño por Reperfusión Miocárdica/patología , Ratas , Ratas Sprague-Dawley , Factores de Tiempo , Factor de Crecimiento Transformador beta/farmacología , Factor de Crecimiento Transformador beta1RESUMEN
BACKGROUND: The sulfonylurea glibenclamide (Glib) abolishes the cardioprotective effect of ischemic preconditioning (IP), presumably by inhibiting mitochondrial K(ATP) channel opening in myocytes. Glimepiride (Glim) is a new sulfonylurea reported to affect nonpancreatic K(ATP) channels less than does Glib. We examined the effects of Glim on IP and on the protection afforded by diazoxide (Diaz), an opener of mitochondrial K(ATP) channels. METHODS AND RESULTS: Rat hearts were Langendorff-perfused, subjected to 35 minutes of regional ischemia and 120 minutes of reperfusion, and assigned to 1 of the following treatment groups: (1) control; (2) IP of 2x 5 minutes each of global ischemia before lethal ischemia; or pretreatment with (3) 30 micromol/L Diaz, (4) 10 micromol/L Glim, (5) 10 micromol/L Glib, (6) IP+Glim, (7) IP+Glib, (8) Diaz+Glim, or (9) Diaz+Glib. IP limited infarct size (18.5+/-1% vs 43.7+/-3% in control, P<0.01) as did Diaz (22.2+/-4.7%, P<0.01). The protective actions of IP or Diaz were not abolished by Glim (18.5+/-3% in IP+Glim, 22.3+/-3% in Diaz+Glim; P<0.01 vs control). However, Glib abolished the infarct-limiting effects of IP and Diaz. Patch-clamp studies in isolated rat ventricular myocytes confirmed that both Glim and Glib (each at 1 micromol/L) blocked sarcolemmal K(ATP) currents. However, in isolated cardiac mitochondria, Glim (10 micromol/L) failed to block the effects of K(ATP) opening by GTP, in contrast to the blockade caused by Glib. CONCLUSIONS: Although it blocks sarcolemmal currents in rat cardiac myocytes, Glim does not block the beneficial effects of mitochondrial K(ATP) channel opening in the isolated rat heart. These data may have significant implications for the treatment of type 2 diabetes in patients with ongoing ischemic heart disease.
Asunto(s)
Diazóxido/farmacología , Hipoglucemiantes/farmacología , Precondicionamiento Isquémico Miocárdico , Isquemia Miocárdica/prevención & control , Compuestos de Sulfonilurea/farmacología , Animales , Gliburida/farmacología , Guanosina Trifosfato/farmacología , Corazón/efectos de los fármacos , Corazón/fisiopatología , Ventrículos Cardíacos/citología , Ventrículos Cardíacos/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Técnicas In Vitro , Membranas Intracelulares/efectos de los fármacos , Membranas Intracelulares/fisiología , Masculino , Potenciales de la Membrana/efectos de los fármacos , Proteínas de la Membrana/efectos de los fármacos , Mitocondrias Cardíacas/efectos de los fármacos , Mitocondrias Cardíacas/fisiología , Infarto del Miocardio/etiología , Infarto del Miocardio/patología , Infarto del Miocardio/prevención & control , Isquemia Miocárdica/complicaciones , Técnicas de Placa-Clamp , Canales de Potasio , Ratas , Ratas Sprague-Dawley , Función VentricularRESUMEN
Ischaemia-reperfusion injury causes cell death by both necrosis and apoptosis. Caspase activation is a major event in apoptosis. We therefore examined the effect of caspase inhibitors during reperfusion upon myocardial infarction. Rat isolated hearts were subjected to 35 min coronary occlusion and 120 min reperfusion. Treatment groups were perfused with caspase inhibitors during early reperfusion. We assessed a non-selective caspase inhibitor (Z-VAD. fmk, 0.1 microM), a caspase-8 inhibitor (Z-IETD.fmk, 0.07 microM), a caspase-9 inhibitor (Z-LEHD.fmk, 0.07 microM) and a caspase-3 inhibitor (Ac-DEVD.cmk, 0.07 microM). All caspase inhibitors limited infarct size (infarct-risk ratio per cent: control 38.5+/-2.6; Z-VAD. fmk 24.6+/-3.4; Z-LEHD.fmk 19.3+/-2.4; Z-IETD.fmk 23.0+/-5.4; Ac-DEVD.cmk 27.8+/-3.3; P<0.05 when compared with control value, 1-way ANOVA). We conclude that caspase inhibition during early reperfusion protects myocardium against lethal reperfusion injury.
Asunto(s)
Inhibidores de Caspasas , Inhibidores de Cisteína Proteinasa/uso terapéutico , Infarto del Miocardio/prevención & control , Daño por Reperfusión Miocárdica/prevención & control , Oligopéptidos/uso terapéutico , Clorometilcetonas de Aminoácidos/uso terapéutico , Animales , Técnicas In Vitro , Masculino , Infarto del Miocardio/enzimología , Daño por Reperfusión Miocárdica/enzimología , Ratas , Ratas Sprague-DawleyRESUMEN
There is debate concerning the involvement of p38 mitogen activated protein kinase (MAPK) in the mediation of ischaemic preconditioning. Pharmacological inhibition of p38 MAPK with SB203580 has been reported to block preconditioning in some studies but not in others. We hypothesised that this divergence could be due to differences in the timing of inhibitor administration. Isolated rat hearts were perfused in the Langendorff mode and subjected to 35 min regional ischaemia followed by 120 min reperfusion. Hearts were then double stained with Evans' blue and triphenyltetrazolium chloride to determine risk (R) and infarct zones (I), expressed as I/R% ratios. Preconditioned hearts were subjected to 2 times 5 min global ischaemia with 10 min intervening reperfusion. SB203580 10 microM was perfused either during the preconditioning protocol (PC+/-SB-early),just prior to and during the first 15 min of the lethal ischaemia (PC+/-SB-late) or prior to regional ischaemia in the absence of preconditioning. Ischaemic preconditioning significantly limited infarct size (I/R 38.9 +/- 3.0% in control vs 13.4 +/- 2.4%, P < 0.01). In the PC+/-SB-early group, preconditioning was still fully protective (I/R% 14.6 +/- 1.0). However, in the PC+/-SB-late group, SB203580 completely blocked the protection afforded by preconditioning (I/R% 33.6 +/- 4.4%, P < 0.01 vs 13.4 +/- 2.4% in preconditioned hearts, p < 0.05). SB203580 alone did not affect infarct size when given prior to and during regional ischaemia (I/R 36.2 +/- 2.7%). These histological data are corroborated by a significant increase in p38 MAPK activation in the preconditioned hearts during sustained ischaemia in comparison with the controls. In conclusion the activation of p38 MAPK during lethal ischaemia, but not during the ischaemic preconditioning protocol, is essential for the mediation of protection and may resolve some of the earlier controversy surrounding the use of SB203580 in preconditioning studies.
Asunto(s)
Inhibidores Enzimáticos/administración & dosificación , Corazón/efectos de los fármacos , Imidazoles/administración & dosificación , Precondicionamiento Isquémico , Proteínas Quinasas Activadas por Mitógenos/antagonistas & inhibidores , Piridinas/administración & dosificación , Animales , Circulación Coronaria/efectos de los fármacos , Esquema de Medicación , Inhibidores Enzimáticos/farmacología , Corazón/fisiopatología , Imidazoles/farmacología , Técnicas In Vitro , Masculino , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Infarto del Miocardio/patología , Infarto del Miocardio/fisiopatología , Miocardio/enzimología , Fosforilación , Presión , Piridinas/farmacología , Ratas , Ratas Sprague-Dawley , Función Ventricular Izquierda/efectos de los fármacos , Proteínas Quinasas p38 Activadas por MitógenosRESUMEN
Mibefradil is a novel calcium channel blocker with activity at both L-type and T-type calcium channels. There are data suggesting that this compound can protect the ischemic/reperfused myocardium in spite of the fact that there is a very low abundance of T-type calcium channels within ventricular tissue. The aims of this study were two-fold. First, we wished to study the protective effect of mibefradil on ischemia/reperfusion injury in the isolated rat heart using infarct size as the endpoint of injury. In this respect, we compared mibefradil with amlodipine, a well-known and potent L-type calcium channel blocker, and with ischemic preconditioning, an intervention known to reduce infarct size consistently. Secondly, we investigated the possible mechanisms through which protection was achieved. For this second purpose, we examined the effects on protection of glibenclamide (an ATP-dependent K+ channel blocker) and chelerythrine (a protein kinase C inhibitor). Isolated rat hearts were perfused in the Langendorff mode at constant pressure. Control, mibefradil-treated (0.3 microM), mibefradil plus glibenclamide (50 microM), and mibefradil plus chelerythrine (10 microM) treated hearts underwent 35 minutes regional ischemia followed by 120 minutes reperfusion. At the end of the experiments, infarct size was determined with triphenyltetrazolium chloride and was expressed as a percentage of the ischemic risk zone (I/R%). A significant reduction in infarct size with mibefradil treatment was observed (I/R 11.1 +/- 2.1% vs. 35.5 +/- 3.1% in controls). This was comparable with the infarct reduction seen with two 5-minute cycles of ischemic preconditioning (17.7 +/- 2.5%). Amlodipine 0.1 microM, a concentration that caused equivalent coronary vasodilatation as that produced by mibefradil treatment, had no significant effect on infarct size (I/R 29.7 +/- 3.5%). The protective effect of mibefradil was not significantly modified by the presence of the PKC inhibitor chelerythrine 10 microM (I/R 19.1 +/- 4.9%) but was abolished when glibenclamide 50 microM was coadministered with mibefradil prior to ischemia (I/R 28.1 +/- 4.7%). Neither chlelerythrine nor glibenclamide alone had any influence on infarct size. We conclude from these data that mibefradil, unlike amlodipine, markedly reduces infarct size in the rat isolated heart. This protection is sensitive to inhibition by glibenclamide, suggesting that KATP channel opening may be an important additional and novel mechanism of mibefradil's action.
Asunto(s)
Bencimidazoles/uso terapéutico , Bloqueadores de los Canales de Calcio/uso terapéutico , Gliburida/uso terapéutico , Infarto del Miocardio/tratamiento farmacológico , Tetrahidronaftalenos/uso terapéutico , Animales , Progresión de la Enfermedad , Activación Enzimática , Hemodinámica/efectos de los fármacos , Técnicas In Vitro , Precondicionamiento Isquémico Miocárdico , Masculino , Mibefradil , Infarto del Miocardio/patología , Proteína Quinasa C/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Factores de RiesgoRESUMEN
An oxidative insult can induce severe damage, as in the phenomenon of myocardial ischemia and reperfusion. However, there are situations in which the damage is not so obvious (e.g., silent ischemia or aging), and the negative effects will be seen only in time. Our aim was to reveal these small changes in the myofilaments by using the nuclear magnetic resonance (NMR) technique. We used Wistar rat hearts in a constant-pressure Langendorff system, perfused with oxygenated Krebs-Henseleit buffer at 37 degrees C. After 15 minutes of stabilization, the hearts were perfused with buffer supplemented with H2O2 at 50, 75, or 100 micromol/L for 15 or 30 minutes. Fifteen-minute and 45-minute perfusion controls and unperfused hearts were also collected. Heart rate (HR) and left ventricular developed pressure (LVDP) were determined with the help of a latex balloon, inserted in the left ventricle and connected with a pressure transducer. Proton transverse relaxation times (T2) were determined at the end of the experiment. T2 values were measured again in the same tissue fragments after they had been glycerinated and incubated in relaxation and rigor media. The functional parameters (HR, LVDP, coronary flow) were not significantly changed in control and 50 micromol/L H2O2 groups but were increased in the 75 micromol/L H2O2 group and significantly decreased in the 100 micromol/L H2O2 group. T2 is significantly decreased in rigor media starting with 50 micromol/L H2O2 administrated for 30 minutes and does not correlate with dose and duration of the oxidative insult. T2 in rigor is shorter than in relaxation media within the groups, and this difference is increased in the treated hearts.
Asunto(s)
Miocardio/patología , Oxidantes/efectos adversos , Animales , Glicerol/farmacología , Corazón/efectos de los fármacos , Corazón/fisiopatología , Peróxido de Hidrógeno/administración & dosificación , Peróxido de Hidrógeno/efectos adversos , Espectroscopía de Resonancia Magnética , Masculino , Isquemia Miocárdica/inducido químicamente , Isquemia Miocárdica/patología , Oxidantes/administración & dosificación , Protones , Ratas , Ratas Wistar , Factores de Tiempo , VasodilataciónRESUMEN
Previous work suggests that delayed protection against infarction following ischaemic preconditioning of rabbit myocardium may involve the activation of protein kinase C (PKC). Preconditioning in the presence of chelerythrine, an inhibitor of PKC, abolished the late anti-infarct effect of preconditioning. In the studies described here, we tested the hypothesis that direct PKC activation with an analogue of diacylglycerol, the physiological activator of PKC, would invoke an adaptive mechanism leading to enhanced myocardial tolerance to ischaemia 24 h later. Rabbits were treated with i.v. injections of 1,2-dioctanoyl-sn-glycerol (DiC8) 5 mg/kg or 15 mg/kg or an equivalent volume of vehicle solution. Twenty-four h after pretreatment, the animals were anaesthetised and underwent 30 min coronary artery occlusion with 120 min reperfusion. Infarct size was determined by triphenyltetrazolium staining. In vehicle pretreated rabbits, infarct-risk zone ratio was 32.8+/-2.6%. Pretreatment with DiC8 5 mg/kg did not significantly affect infarct size (26.3+/-4.0%), but pretreatment with DiC8 15 mg/kg resulted in a marked reduction in infarct size (18.0+/-3.4%, P<0.05, 1-way ANOVA). Reduction in infarct size with the higher dose of DiC8 was independent of myocardial risk zone size and systemic haemodynamic parameters during coronary occlusion. The haemodynamic effects of acute administration of DiC8 15 mg/kg were examined in a separate cohort of pentobarbitone-anaesthetised rabbits. The compound was found not to affect systolic blood pressure or heart rate under these conditions. We examined the possibility that increased ischaemic tolerance might be due to induction of the 27 and 72 kDa heat shock proteins (hsp27 and hsp70i) which are known to be cytoprotective and are upregulated by ischaemia and other stressful stimuli. Western blot analysis of left ventricular tissue revealed that neither protein was induced 24 h after treatment with DiC8 15 mg/kg. Thus, infarct limitation 24 h after DiC8 treatment did not appear to be due to increased tissue content of these proteins. The mechanisms of DiC8-induced delayed myocardial protection remain unclear. However, these data are compatible with the hypothesis that activation of PKC isoenzymes is an important intermediate signal of sub-acute cellular adaptation, and results in enhanced tolerance to ischaemia-reperfusion injury in myocardium many hours later.
Asunto(s)
Diglicéridos/farmacología , Isquemia Miocárdica/tratamiento farmacológico , Proteína Quinasa C/metabolismo , Animales , Presión Sanguínea , Activación Enzimática , Frecuencia Cardíaca , Proteínas de Choque Térmico/metabolismo , Hemodinámica , Concentración de Iones de Hidrógeno , Masculino , Infarto del Miocardio/patología , Conejos , Daño por Reperfusión/metabolismo , Factores de TiempoRESUMEN
The present study investigated whether protein kinase C (PKC) plays a role in ischemic preconditioning in the rat heart. Chelerythrine, a specific antagonist of PKC, and 1,2-dioctanoyl-sn-glycerol (DOG), a diacylglycerol analogue and specific antagonist of PKC, were used to determine whether preconditioning could be blocked or triggered, respectively. Sprague-Dawley rats were anesthetized and instrumented for coronary occlusion and reperfusion. All animals were subjected to 45 minutes of regional ischemia (ISC) followed by 2.5 hours of reperfusion. The preconditioning protocol consisted of 5 minutes of ischemia and then 10 minutes of reperfusion. There were six groups: (1) control (group C, n = 5), (2) preconditioned and ISC (group PC, n = 6), (3) chelerythrine given 2 minutes before ISC (group CC, n = 5), (4) preconditioned and chelerythrine given 2 minutes before ISC (group PCC, n = 6), (5) DOG (dissolved in dimethylsulfoxide [DMSO]) given 10 minutes before ISC (group CD, n = 5), and (6) DMSO given 10 minutes before ISC (group DMSO, n = 3). The end point was infarct size measured using triphenyl tetrazolium chloride and expressed as a percentage of the volume at risk (I/R), measured with fluorescent particles. I/R was significantly reduced by preconditioning (group C, 58.6 +/- 5.0%; group PC, 32.7 +/- 6.3%; P < .01) and by the PKC agonist DOG, which reduced I/R to a similar extent as preconditioning (group C, 58.6 +/- 5.0%; group CD, 28.0 +/- 7.0%; P < .01).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Diglicéridos/farmacología , Infarto del Miocardio/fisiopatología , Isquemia Miocárdica/fisiopatología , Reperfusión Miocárdica , Fenantridinas/farmacología , Proteína Quinasa C/metabolismo , Alcaloides , Análisis de Varianza , Animales , Arritmias Cardíacas/fisiopatología , Benzofenantridinas , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Peso Corporal/efectos de los fármacos , Vasos Coronarios/fisiología , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Masculino , Infarto del Miocardio/enzimología , Isquemia Miocárdica/enzimología , Tamaño de los Órganos/efectos de los fármacos , Proteína Quinasa C/antagonistas & inhibidores , Ratas , Ratas Sprague-DawleyRESUMEN
Prior heat stress leads to an enhancement of postischemic mechanical function and improvement in biochemical indices of injury in the rat heart, associated with an elevation in endogenous catalase activity. We have examined the effect of heat stress on free radical release during reperfusion in the isolated rat heart using electron spin resonance (ESR). Twenty four hours after heat stress or sham treatment, hearts were perfused in the Langendorff mode and subjected to 10 min of no-flow global ischemia followed by 10 min of reperfusion. Coronary effluent was collected at specific time points in PBN for ESR measurement. A PBN adduct was identified with characteristics consistent with an alkoxyl radical: PBN-LO. In sham hearts there was a rapid rise in adduct release to a maximum (228 +/- 15% of stabilization values, p < .05) occurring 1 min into reperfusion. In heat stress hearts there was no significant rise in adduct release during the reperfusion period. Pretreatment of hearts with 3-amino triazole, an inhibitor of catalase, failed to clarify whether the protection seen in heat stress hearts was a result of the elevation in catalase activity. These results suggest that heat stress protects the myocardium against the oxidative stress of ischemia-reperfusion.
Asunto(s)
Calor , Miocardio/metabolismo , Animales , Catalasa , Espectroscopía de Resonancia por Spin del Electrón , Radicales Libres , Hemodinámica , Masculino , Isquemia Miocárdica , Reperfusión Miocárdica , Perfusión , Ratas , Ratas Sprague-DawleyRESUMEN
The present study was carried out on the uptake of 125I-insulin in the tissues or organs (liver, subcutaneous adipose tissue, striated muscle, renal cortex, frontal lobes of the brain) of normal Wistar rats or from animals treated with benzo(a)pyrene, a powerful carcinogen which s metabolically activated in the liver. The carcinogen was administered as follows: (a) in adult life by a single injected dose; (b) in early fetal life by administration to pregnant females and (c) in late fetal life, likewise by administration to the mothers. The results of combined administrations were studied as well. The ability of normal tissues to take up insulin was determined. The administration of a single benzo(a)pyrene dose produced marked alterations in binding of the hormone in some of the tissues, which might be attributed to certain general changes in the properties of the cell membranes. It has to be underlined that after the contact with the carcinogen in fetal life, the tissular ability to take up insulin is irreversibly and non-uniformly altered. This ability is easily influenced by a new carcinogenic dose.
Asunto(s)
Benzo(a)pireno/toxicidad , Insulina/metabolismo , Neoplasias Experimentales/inducido químicamente , Animales , Femenino , Radioisótopos de Yodo , Masculino , Neoplasias Experimentales/metabolismo , Embarazo , Efectos Tardíos de la Exposición Prenatal , Unión Proteica/efectos de los fármacos , Ratas , Ratas Wistar , Receptor de Insulina/efectos de los fármacos , Receptor de Insulina/metabolismoRESUMEN
Starting from the existence of some autoimmune diseases (i.e. bronchial asthma or miastenia gravis) we asked ourselves if some plasmatic factors do exist, influencing the receptor--mediator relations in cardiovascular system during some illnesses having unknown etiology, as arterial hypertension. For this reason, in this work was tested the hypothesis that, in some chronic cardiovascular diseases would exist factors circulating and affecting the functions of the cellular membranes of the arterial wall, particularly of the smooth muscle cells and myocardial cells. Our results show a significant modification of the calcium fluxes and of some neuromediators uptake at the hypertensive patients.